LIN-2003

Regimen

Experimental
Concurrent cisplatin 20 mg/m²/d + 5-FU 400 mg/m²/d by 96h continuous infusion on weeks 1 and 5 of RT
Control
Radiotherapy alone

Population

Stage III-IV (M0) NPC, Taiwanese population (predominantly non-keratinizing/undifferentiated WHO type II/III)

Key finding

Confirmed INT-0099 findings in an endemic-area East Asian population with predominantly WHO type II/III histology. Five-year OS advantage of 18% for CCRT over RT alone established the generalisability of CCRT outside North America. Use of a lower-intensity concurrent regimen (split-course cisplatin/5-FU) rather than q3w cisplatin demonstrated that the CCRT benefit is robust to schedule variation.

Source: PMID 12586799

Timeline

    Guideline citations

    • NCCN NPC (p.246)